Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICIs) can yield remarkable clinical responses in subsets of patients with solid tumors but can also often lead to immune-related adverse events (irAEs). Predictive features of clinically severe irAEs leading to cessation of ICIs have yet to be established. Using data from 1,327 patients with lung cancer treated with ICIs between 2009 and 2022 at four academic medical centers, we evaluated the association of a germline polygenic risk score for autoimmune disease and discontinuation of ICIs due to irAEs.

Methods

Using Cox proportional hazards model, we assessed the association between a polygenic risk score for autoimmune disease (PRS_AD) and cessation of ICI therapy due to irAEs. All models were adjusted for age at diagnosi

SUBMITTER: Middha P 

PROVIDER: S-EPMC11213033 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature